Clinical features of Sjogren's syndrome in patients with multiple sclerosis

Annunziata P, De Santi L, Di Rezze S, Millefiorini E, Capello E, Mancardi G, De Riz M, Scarpini E, Vecchio R, Patti F. Clinical features of Sjogren’s syndrome in patients with multiple sclerosis. 
Acta Neurol Scand: 2011: 124: 109–114.
© 2010 John Wiley & Sons A/S. Objectives –  To assess the fr...

Full description

Saved in:
Bibliographic Details
Published inActa neurologica Scandinavica Vol. 124; no. 2; pp. 109 - 114
Main Authors Annunziata, P., De Santi, L., Di Rezze, S., Millefiorini, E., Capello, E., Mancardi, G., De Riz, M., Scarpini, E., Vecchio, R., Patti, F.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.08.2011
Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Annunziata P, De Santi L, Di Rezze S, Millefiorini E, Capello E, Mancardi G, De Riz M, Scarpini E, Vecchio R, Patti F. Clinical features of Sjogren’s syndrome in patients with multiple sclerosis. 
Acta Neurol Scand: 2011: 124: 109–114.
© 2010 John Wiley & Sons A/S. Objectives –  To assess the frequency of clinical features of Sjogren’s syndrome (SS) in patients with multiple sclerosis (MS) receiving treatment with disease‐modifying drugs (DMDs) or naïve to treatment and the possible association with clinical, cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) parameters. Methods –  A multicentre cross‐sectional observational study was designed, based on a structured neurologist‐administered questionnaire to 440 patients. Results –  Twenty‐eight of 230 (12%) patients receiving treatment with DMDs (DMDs+) and 14 of 210 (6.6%) treatment‐naïve patients (DMDs−) showed clinical features of SS. Four primary SS were diagnosed, two of which were DMDs+ and two were DMDs−. Sicca symptoms were significantly associated with higher EDSS scores (P = 0.018), a low frequency of gadolinium‐enhanced MRI‐positive lesions (P = 0.018) and cerebral disturbances (P = 0.001). Conclusions –  Screening for the clinical features of SS should be performed in patients with MS both receiving treatment with immunomodulatory drugs and without therapy.
Bibliography:ark:/67375/WNG-ZN5H3JFZ-G
istex:44114DA9680F874DE6B34A5C9AB0F9B7F59EBDAA
ArticleID:ANE1428
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0001-6314
1600-0404
DOI:10.1111/j.1600-0404.2010.01428.x